Enanta Pharmaceutica (ENTA)

$10.51 -0.16 (-1.50%)
Market Cap 228.10M
Revenue (ttm) 67.64M
Net Income (ttm) -116.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -171.57%
Debt to Equity Ratio 0.00
Volume 357,200
Avg Vol 778,266
Day's Range N/A - N/A
Shares Out 21.38M
Stochastic %K 17%
Beta 0.89
Analysts Strong Sell
Price Target $17.67

Company Profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 607 0800
Fax: 617 607 0530
Address:
4 Kingsbury Avenue, Watertown, United States
BullJack
BullJack Oct. 21 at 7:38 AM
$ENTA Deep Track liked their data on the 29th and bought a significant stake after the cooldown. One to watch On October 2, 2025, Deep Track Capital, LP (Trades, Portfolio) executed a noteworthy transaction by acquiring 1,484,513 shares of Enanta Pharmaceuticals Inc. This acquisition was made at a price of $10.33 per share
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 16 at 1:40 PM
$ENTA they diluted at $10 and those shares will start being sold soon. This is being propped upup by broker just to sell big soon
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 15 at 7:16 PM
$ENTA short more
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 15 at 6:33 PM
$ENTA short
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 14 at 10:27 PM
$ENTA starting to curl down
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 14 at 4:39 PM
$ENTA broker keeps propping this up everything it goes under 11. Soon they will lose interest and it will crater
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 13 at 2:26 PM
$ENTA no volume. One big sell away from going under $10
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 13 at 12:19 PM
$ENTA Cycle Trading Signal plugged into AI 🔥 lists
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 10 at 6:54 PM
$ENTA I wonder why no insiders are buying after latest trial? Oh yeah, it failed and they diluted. Likely to continue diluting
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 10 at 3:15 PM
$ENTA likely back to offering price
0 · Reply
Latest News on ENTA
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

Oct 20, 2025, 7:00 AM EDT - 5 days ago

Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

Oct 7, 2025, 7:00 AM EDT - 18 days ago

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 2, 2025, 4:01 PM EDT - 23 days ago

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Oct 1, 2025, 8:16 AM EDT - 24 days ago

Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

CALM

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Sep 30, 2025, 9:00 PM EDT - 24 days ago

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sep 30, 2025, 4:11 PM EDT - 25 days ago

Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock

Enanta Pharmaceuticals, Inc. - Special Call

Sep 29, 2025, 3:47 PM EDT - 26 days ago

Enanta Pharmaceuticals, Inc. - Special Call

Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change

Sep 29, 2025, 2:40 PM EDT - 26 days ago

Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change

Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Sep 29, 2025, 6:30 AM EDT - 26 days ago

Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Sep 26, 2025, 4:01 PM EDT - 4 weeks ago

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

Sep 3, 2025, 6:00 AM EDT - 7 weeks ago

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

Enanta Pharmaceuticals to Participate in September Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 2 months ago

Enanta Pharmaceuticals to Participate in September Investor Conferences

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

Aug 20, 2025, 7:00 AM EDT - 2 months ago

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

Aug 11, 2025, 4:02 PM EDT - 2 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Aug 5, 2025, 7:00 AM EDT - 2 months ago

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series

Jul 15, 2025, 7:00 AM EDT - 3 months ago

Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

Jun 11, 2025, 12:34 PM EDT - 4 months ago

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 27, 2025, 7:00 AM EDT - 5 months ago

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

May 22, 2025, 7:00 AM EDT - 5 months ago

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

May 12, 2025, 4:01 PM EDT - 5 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Apr 8, 2025, 7:00 AM EDT - 7 months ago

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 17, 2025, 7:00 AM EDT - 7 months ago

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

Mar 12, 2025, 7:00 AM EDT - 8 months ago

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Feb 10, 2025, 4:01 PM EST - 9 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 7:00 AM EST - 10 months ago

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Dec 24, 2024, 7:00 AM EST - 10 months ago

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Dec 9, 2024, 6:30 AM EST - 11 months ago

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Dec 6, 2024, 5:00 PM EST - 11 months ago

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024

Nov 25, 2024, 4:01 PM EST - 11 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Sep 26, 2024, 6:00 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals to Participate in Investor Conferences in September

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Participate in Investor Conferences in September

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

May 29, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

May 7, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript

May 6, 2024, 8:34 PM EDT - 1 year ago

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

May 6, 2024, 4:01 PM EDT - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2024, 7:10 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Apr 17, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Mar 6, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

Feb 7, 2024, 10:04 PM EST - 1 year ago

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

Feb 7, 2024, 4:01 PM EST - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023

Jan 31, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Enanta: Multiple Shots On Goal For RSV Makes This A Must Watch

Nov 30, 2023, 3:34 PM EST - 2 years ago

Enanta: Multiple Shots On Goal For RSV Makes This A Must Watch

Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

Nov 22, 2023, 7:00 AM EST - 2 years ago

Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

Enanta Pharmaceuticals, Inc. (ENTA) Q4 2023 Earnings Call Transcript

Nov 20, 2023, 9:43 PM EST - 2 years ago

Enanta Pharmaceuticals, Inc. (ENTA) Q4 2023 Earnings Call Transcript

BullJack
BullJack Oct. 21 at 7:38 AM
$ENTA Deep Track liked their data on the 29th and bought a significant stake after the cooldown. One to watch On October 2, 2025, Deep Track Capital, LP (Trades, Portfolio) executed a noteworthy transaction by acquiring 1,484,513 shares of Enanta Pharmaceuticals Inc. This acquisition was made at a price of $10.33 per share
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 16 at 1:40 PM
$ENTA they diluted at $10 and those shares will start being sold soon. This is being propped upup by broker just to sell big soon
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 15 at 7:16 PM
$ENTA short more
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 15 at 6:33 PM
$ENTA short
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 14 at 10:27 PM
$ENTA starting to curl down
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 14 at 4:39 PM
$ENTA broker keeps propping this up everything it goes under 11. Soon they will lose interest and it will crater
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 13 at 2:26 PM
$ENTA no volume. One big sell away from going under $10
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 13 at 12:19 PM
$ENTA Cycle Trading Signal plugged into AI 🔥 lists
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 10 at 6:54 PM
$ENTA I wonder why no insiders are buying after latest trial? Oh yeah, it failed and they diluted. Likely to continue diluting
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 10 at 3:15 PM
$ENTA likely back to offering price
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 10 at 2:00 PM
$ENTA volume is really drying up here
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 10 at 11:31 AM
$ENTA likely many years away if ever
0 · Reply
justiceforb_85
justiceforb_85 Oct. 10 at 1:45 AM
$ENTA continuing to accumulate. Zelicapavir should be the first anti-viral for RSV approved in the US.
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 9 at 4:14 PM
$ENTA 30k shares dumped at noon. Ouch
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 9 at 1:36 PM
$ENTA easy stock to short. Hits a wall every day and gets rejected
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 7 at 8:02 PM
$ENTA diluted massively at $10 per share after missing end points in latest trial
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 7 at 8:02 PM
$ENTA brokers still propping it up. Won’t last much longer then it will dive under $10
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 7 at 12:22 PM
$ENTA stock hasn’t gained any over past year and now back to single digits before long. Failed trial then unexpectedly diluted stockholders with massive offering under current market price
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 6 at 11:36 PM
$ENTA soon back to single digits. Loaded more powder to short this. Let’s see if I can get a good entry tomorrow for more
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 6 at 6:43 PM
$ENTA missed last trial by long shot. Had a huge offering. Huge failure for investors
0 · Reply
momyurich
momyurich Oct. 6 at 5:23 PM
$ENTA 📈
0 · Reply
RamGuy_949322
RamGuy_949322 Oct. 6 at 3:53 PM
$ENTA hmm falling knife
0 · Reply